Clinical trials: Bronchogenic Cancer
Non-small Cell Lung Cancer, EGFR G719X
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Furmonertinib, a newly-designed pan-EGFR-TKI with a trifluoroethoxypyridine-based molecule structure, has shown promising clinical efficacy in EGFR Ex19del/L858R/T790M/Ex20ins mutant advanced NSCLC with an acceptable safety…
- Conditions
- Non-small Cell Lung Cancer, EGFR G719X, EGFR L861Q, EGFR S768I
- Trial name
- NCT05548348
- Testing
- Furmonertinib 160 mg, Q.D.
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Carcinoma, Non-small Cell Lung Cancer
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
Conduct a prospective study in multicenter to confirm the value of circulating tumor DNA in longitudinal monitoring of stage III-IV lung cancer patients.
- Conditions
- Carcinoma, Non-small Cell Lung Cancer, Lung Neoplasm
- Trial name
- NCT03664843
- Where
- 8 sites in China
- Volunteers
- 120 people
- Sponsor
- First Hospital of Shijiazhuang City
Advanced Non-small Cell Lung Cancer
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
The main object of this trial is to offer treatment of recombinant endostatin ( Sulijia) combined with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer, expecting to…
- Trial name
- NCT03117335
- Testing
- Sulijia
- Where
- 37 sites in China
- Volunteers
- 560 people
- Sponsor
- Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Lung Cancer
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00098917
- Testing
- autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-Small-Cell Lung Cancer
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
The purpose of the Phase 1b part of the study was to evaluate the safety and tolerability of ASP2215 in combination with erlotinib and determine the recommended phase 2 dose (RP2D) of ASP2215.
- Trial name
- NCT02495233
- Testing
- Gilteritinib, Erlotinib
- Where
- 4 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Lung Cancer, Thoracic Cancer
Prospective Data Collection Initiative on Thoracic Malignancies
Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome.
- Conditions
- Lung Cancer, Thoracic Cancer, Lung Cancer, Nonsmall Cell, Adenocarcinoma
- Trial name
- DuTOC (NCT06996249)
- Testing
- Health-related quality of life and treatment outcome questionnaires, (Tumor) tissue and other biomaterials, Blood samples
- Where
- 23 sites in Netherlands
- Volunteers
- 12,000 people
- Sponsor
- Dutch Society of Physicians for Pulmonology and Tuberculosis
Non-small Cell Lung Cancer
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).
- Trial name
- NCT05788926
- Testing
- TG6050
- Where
- 5 sites in France
- Volunteers
- 22 people
- Sponsor
- Transgene
Lung Cancer (Non-Small Cell), Sarcopenia
Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery
This prospective observational cohort study aims to evaluate the prognostic value of multimodal nutritional status and sarcopenia assessment in patients undergoing lung cancer surgery.
- Conditions
- Lung Cancer (Non-Small Cell), Sarcopenia, Malnutrition Severe
- Trial name
- NCT07500376
- Testing
- Observational Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 142 people
- Sponsor
- Ondokuz Mayıs University
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
NSCLC
Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)
Despite recent advances in the treatment of NSCLC overall survival within these patients remains dismal and there is yet an unmet medical need for additional treatment options.
- Trial name
- NCT01368848
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 3 sites in Austria
- Volunteers
- 7 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Lung Cancer
Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer
RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer.
- Trial name
- NCT00003726
- Testing
- lepirudin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Non-Small Cell Lung Cancer, ICI-refractory
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.
- Trial name
- NCT07133425
- Testing
- SAR445877
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Malignant Mesothelioma
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
- Trial name
- NCT00024076
- Testing
- radiofrequency ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Different people have different biomarkers (chemical "markers" in the blood that may be related to your reaction to study drugs).
- Trial name
- NCT01248247
- Testing
- Erlotinib, AZD6244, MK-2206
- Where
- 2 sites in United States
- Volunteers
- 334 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost…
- Trial name
- HP-SIB-AHFRT (NCT07823855)
- Testing
- hyperfractionated radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Anorexia, Cachexia
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in limiting weight loss in patients who are undergoing radiation therapy.
- Conditions
- Anorexia, Cachexia, Lung Cancer
- Trial name
- NCT00031785
- Testing
- megestrol acetate, radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer, Head and Neck Cancer
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00820417
- Testing
- Cetuximab/Gefitinib combination and/or monotherapy
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 63 people
- Sponsor
- Harrison Clinical Research
Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
This phase II trial is studying the side effects and how well giving radiation therapy together with bevacizumab, paclitaxel, and carboplatin works in treating patients with unresectable stage IIIB or stage IV non-small cell lung…
- Conditions
- Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, Hemoptysis, Squamous Cell Lung Cancer
- Trial name
- NCT00387374
- Testing
- bevacizumab, paclitaxel, carboplatin
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer (NSCLC), HER2 Expression
Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer
The investigators investigate whether PET imaging with ⁸⁹Zr-trastuzumab can reliably demonstrate the extent of tracer accumulation in tumors of patients with HER2-mutated or HER2-overexpressing non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation
- Trial name
- NCT07436858
- Testing
- PET imaging with ⁸⁹Zr-trastuzumab, Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.